[ANIK] Anika Therapeutics Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 49.53 Change: 0.9 (1.85%)
Ext. hours: Change: 0 (0%)

chart ANIK

Refresh chart

Strongest Trends Summary For ANIK

ANIK is in the medium-term down -19% below S&P in 4 months. In the long-term up 261% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company?s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company?s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regen

Fundamental Ratios
Shares Outstanding EPS2.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -40.93% Sales Growth - Q/Q-33.26% P/E21.89
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA13.56% ROE14.74% ROI
Current Ratio23.7 Quick Ratio21.67 Long Term Debt/Equity Debt Ratio0.03
Gross Margin76.03% Operating Margin49.46% Net Profit Margin30.77% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.9 M Cash From Investing Activities-6.01 M Cash From Operating Activities3.98 M Gross Profit17.63 M
Net Profit7.82 M Operating Profit12.43 M Total Assets208.01 M Total Current Assets155.73 M
Total Current Liabilities7.96 M Total Debt Total Liabilities17.44 M Total Revenue22.9 M
Technical Data
High 52 week68.43 Low 52 week30.16 Last close33.37 Last change-1.68%
RSI28.12 Average true range1.5 Beta0.55 Volume53.19 K
Simple moving average 20 days-12.46% Simple moving average 50 days-5.2% Simple moving average 200 days-30.71%
Performance Data
Performance Week-15.56% Performance Month-8.45% Performance Quart-24.07% Performance Half-50.76%
Performance Year-35.45% Performance Year-to-date-0.71% Volatility daily3.96% Volatility weekly8.86%
Volatility monthly18.15% Volatility yearly62.89% Relative Volume229.99% Average Volume131.63 K
New High New Low


2019-06-14 17:25:09 | Dr. Reddy's Inks Deal to Sell Neurology Branded Products

2019-06-13 10:26:02 | Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

2019-06-12 15:51:01 | Are Insiders Selling Anika Therapeutics, Inc. NASDAQ:ANIK Stock?

2019-06-12 09:39:01 | Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

2019-06-11 18:18:10 | Novavax' Shares Drop as FDA Advises Another Study for Resvax

2019-06-10 17:30:09 | Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

2019-06-05 08:00:00 | Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Cartilage Repair Scaffold at the 2019 International Cartilage Regeneration and Joint Preservation Society ICRS Focus Meeting

2019-06-04 16:16:08 | bluebird's Zynteglo Gets EU Conditional Marketing Approval

2019-06-04 10:26:02 | Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

2019-06-04 09:01:01 | uniQure QURE Jumps: Stock Rises 8.9%

2019-06-03 16:48:08 | Alnylam Initiates Phase I Study on Hypertension Candidate

2019-05-30 08:44:12 | Fibrocell Up on FDA Designation for Gene Therapy Candidate

2019-05-30 08:28:12 | Amarin Rises on Priority Review for Vascepa Label Expansion

2019-05-29 10:40:02 | Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

2019-05-28 09:02:01 | Epizyme EPZM Shares Surge More Than 100% YTD: Here's Why?

2019-05-27 05:00:09 | Dynavax DVAX to Cut Jobs and Focus on Vaccine Business

2019-05-24 11:43:03 | Guardant Health GH Looks Good: Stock Adds 6% in Session

2019-05-24 10:53:02 | Agenus' AGEN Pipeline Progression on Track Amid Competition

2019-05-23 14:25:06 | Affimed AFMD Earnings and Sales Exceed Estimates in Q1

2019-05-22 09:44:01 | OncoSec Medical ONCS Looks Good: Stock Adds 6.6% in Session

2019-05-20 15:06:07 | Dr. Reddy's RDY Q4 Earnings Up Y/Y, Revenues Top Estimates

2019-05-16 08:42:12 | BioMarin BMRN in Focus: Stock Moves 7.5% Higher

2019-05-14 09:05:01 | Regeneron REGN Gets FDA Nod for Eylea Label Expansion

2019-05-14 08:41:12 | Twist Bioscience TWST Catches Eye: Stock Jumps 8%

2019-05-13 09:13:01 | Achillion ACHN Reports Wider-Than-Expected Loss in Q1

2019-05-13 08:30:00 | Anika to Showcase Regenerative Medicine and Orthobiologics Portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress

2019-05-13 05:36:09 | Will Anika Therapeutics Continue to Surge Higher?

2019-05-09 20:34:15 | Here’s What Hedge Funds Think About Anika Therapeutics, Inc. ANIK

2019-05-08 16:13:08 | 6 Stocks That Popped Last Week

2019-05-06 08:30:00 | Anika to Participate in Two Investor Events in May 2019

2019-05-06 07:23:11 | What You Must Know About Anika Therapeutics, Inc.'s NASDAQ:ANIK Beta Value

2019-05-02 22:26:36 | Anika Therapeutics Inc ANIK Q1 2019 Earnings Call Transcript

2019-05-02 18:25:10 | Anika Therapeutics ANIK Q1 Earnings and Revenues Top Estimates

2019-05-02 17:19:34 | Anika: 1Q Earnings Snapshot

2019-05-02 16:05:00 | Anika Reports First Quarter 2019 Financial Results

2019-05-02 16:02:00 | Anika Announces $50 Million Share Repurchase Program

2019-04-30 16:05:00 | Anika Appoints Stephen Goldy as Vice President of U.S. Sales

2019-04-25 10:34:02 | Anika Therapeutics ANIK Reports Next Week: Wall Street Expects Earnings Growth

2019-04-18 16:05:00 | Anika to Issue First-Quarter 2019 Financial Results and Business Highlights on Thursday, May 2

2019-04-04 15:33:15 | Imagine Owning Anika Therapeutics NASDAQ:ANIK And Wondering If The 33% Share Price Slide Is Justified

2019-04-03 16:05:00 | Anika to Highlight Regenerative Medicine and Orthobiologics Portfolio at 2019 Asia Pacific Orthopaedic Association Sports Meeting

2019-03-18 08:30:00 | Anika Appoints Robert Richard, Ph.D. as Vice President of Research and Development

2019-03-11 16:05:00 | Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting

2019-03-06 02:20:36 | Edited Transcript of ANIK earnings conference call or presentation 27-Feb-04 4:00pm GMT

2019-03-06 02:18:14 | Edited Transcript of ANIK earnings conference call or presentation 17-Mar-10 1:00pm GMT

2019-02-22 09:46:10 | Anika Therapeutics ANIK Q4 2018 Earnings Conference Call Transcript

2019-02-22 00:10:42 | Edited Transcript of ANIK earnings conference call or presentation 21-Feb-19 10:00pm GMT

2019-02-21 18:55:11 | Anika Therapeutics ANIK Q4 Earnings and Revenues Top Estimates

2019-02-21 18:01:32 | Anika: 4Q Earnings Snapshot

2019-02-21 16:05:00 | Anika Reports Fourth Quarter and Full Year 2018 Financial Results